The FDA approves Novartis’ (NVS +1.4%) Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (MS).
The company expects the nod in Europe by Q2 2021.
The company markets the CD20-directed cytolytic antibody as Arzerra for chronic lymphocytic leukemia.
It was discovered by Genmab A/S (GMAB +1.9%) who licensed the rights to GlaxoSmithKline (GSK -0.5%) in 2006. Novartis acquired the rights in the autoimmune space from GSK in December 2015.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.